SPARCPharmaceuticals
Sun Pharma Advanced Research Company Ltd — Profit & Loss Statement
₹114.89
-8.03%
Sun Pharma Advanced Research Company Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 8623.86 | 1.13 Cr | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.00 | 0.30 | 0.00 | 0.00 | — |
| Normalized EBITDA | -322.94 Cr | -376.89 Cr | -206.33 Cr | -185.26 Cr | — |
| Total Unusual Items | 1.09 Cr | 3.76 Cr | 3.15 Cr | 5.36 Cr | — |
| Total Unusual Items Excluding Goodwill | 1.09 Cr | 3.76 Cr | 3.15 Cr | 5.36 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Reconciled Depreciation | 12.39 Cr | 12.51 Cr | 11.77 Cr | 10.16 Cr | — |
| Reconciled Cost Of Revenue | 109.96 Cr | 135.79 Cr | 176.74 Cr | 131.07 Cr | — |
| EBITDA | -321.85 Cr | -373.13 Cr | -203.18 Cr | -179.90 Cr | — |
| EBIT | -334.24 Cr | -385.64 Cr | -214.95 Cr | -190.07 Cr | — |
| Net Interest Income | -8.36 Cr | 23.78 Cr | -0.04 Cr | -11.92 Cr | — |
| Interest Expense | 8.54 Cr | 1.19 Cr | 7.63 Cr | 13.33 Cr | — |
| Interest Income | 0.68 Cr | 25.48 Cr | 7.60 Cr | 1.41 Cr | — |
| Normalized Income | -343.60 Cr | -389.85 Cr | -225.74 Cr | -208.75 Cr | — |
| Net Income From Continuing And Discontinued Operation | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Total Expenses | 405.83 Cr | 487.05 Cr | 462.42 Cr | 333.32 Cr | — |
| Rent Expense Supplemental | 0.00 | 0.25 Cr | 0.00 | 0.00 | — |
| Diluted Average Shares | 32.45 Cr | 32.45 Cr | 28.47 Cr | 26.31 Cr | — |
| Basic Average Shares | 32.45 Cr | 32.45 Cr | 28.47 Cr | 26.31 Cr | — |
| Diluted EPS | -10.55 | -11.93 | -7.82 | -7.73 | — |
| Basic EPS | -10.55 | -11.93 | -7.82 | -7.73 | — |
| Diluted NI Availto Com Stockholders | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Net Income Common Stockholders | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Net Income Including Noncontrolling Interests | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Net Income Continuous Operations | -342.51 Cr | -387.21 Cr | -222.58 Cr | -203.40 Cr | — |
| Tax Provision | -0.27 Cr | 0.38 Cr | 0.00 | 0.00 | — |
| Pretax Income | -342.78 Cr | -386.83 Cr | -222.58 Cr | -203.40 Cr | — |
| Other Non Operating Income Expenses | 0.02 Cr | 0.23 Cr | 0.02 Cr | 0.08 Cr | — |
| Special Income Charges | 0.03 Cr | 0.58 Cr | -0.11 Cr | 4.89 Cr | — |
| Other Special Charges | -0.03 Cr | -0.58 Cr | 0.11 Cr | -4.89 Cr | — |
| Net Non Operating Interest Income Expense | -8.36 Cr | 23.78 Cr | -0.04 Cr | -11.92 Cr | — |
| Total Other Finance Cost | 0.50 Cr | 0.50 Cr | — | — | — |
| Interest Expense Non Operating | 8.54 Cr | 1.19 Cr | 7.63 Cr | 13.33 Cr | — |
| Interest Income Non Operating | 0.68 Cr | 25.48 Cr | 7.60 Cr | 1.41 Cr | — |
| Operating Income | -334.06 Cr | -411.50 Cr | -223.64 Cr | -196.07 Cr | — |
| Operating Expense | 295.87 Cr | 351.26 Cr | 285.69 Cr | 202.25 Cr | — |
| Other Operating Expenses | 31.19 Cr | 35.68 Cr | 29.10 Cr | 21.06 Cr | — |
| Depreciation And Amortization In Income Statement | 12.39 Cr | 12.51 Cr | 11.77 Cr | 10.16 Cr | — |
| Depreciation Income Statement | 12.39 Cr | 12.51 Cr | 11.77 Cr | 10.16 Cr | — |
| Selling General And Administration | 93.99 Cr | 154.48 Cr | 133.44 Cr | 69.52 Cr | — |
| General And Administrative Expense | 93.99 Cr | 154.48 Cr | 133.44 Cr | 69.52 Cr | — |
| Rent And Landing Fees | 0.00 | 0.25 Cr | 0.00 | 0.00 | — |
| Gross Profit | -38.19 Cr | -60.24 Cr | 62.04 Cr | 6.17 Cr | — |
| Cost Of Revenue | 109.96 Cr | 135.79 Cr | 176.74 Cr | 131.07 Cr | — |
| Total Revenue | 71.77 Cr | 75.55 Cr | 238.78 Cr | 137.25 Cr | — |
| Operating Revenue | 71.77 Cr | 75.55 Cr | 238.78 Cr | 137.25 Cr | — |
| Write Off | — | — | — | 0.00 | -0.20 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sun Pharma Advanced Research Company Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.